undamentalytics Newsletter
Sign in

60 Degrees Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, 60 Degrees Pharmaceuticals, Inc.'s operations generated −$6.8m of cash; it spent $139,881 on capital projects, leaving free cash flow of −$7.0m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−1,010−4,543−5,648−6,849−8,775
Depreciation and amortisation2821124361
Stock-based pay02133,609456413
Capital spending—58104140120
Free cash flow—−4,601−5,752−6,989−8,895
Free cash flow after stock pay—−4,813−9,361−7,445−9,308
Shares issued1,0481,048———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: SXTC vs SXTPSCNX vs SXTPLPCN vs SXTPNTRB vs SXTP

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from 60 Degrees Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 60 Degrees Pharmaceuticals, Inc.